Rani Therapeutics Holdings (RANI) Other Working Capital Changes (2020 - 2026)
Rani Therapeutics Holdings' (RANI) quarterly Other Working Capital Changes came in at -$477000.0 in Q1 2026, little changed year-on-year from -$476004.2 in Q1 2025, and up 1.24% quarter-over-quarter from -$483000.0 in Q4 2025.
Rani Therapeutics Holdings (RANI) Other Working Capital Changes (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Other Working Capital Changes history runs 7 years deep, the most recent figure standing at -$477000.0 for Q1 2026.
- On a quarterly basis, Other Working Capital Changes changed 0.21% year-over-year to -$477000.0 in Q1 2026; TTM through Mar 2026 was -$1.9 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at -$1.9 million, down 5.59% from the prior year.
- Other Working Capital Changes advanced to -$477000.0 in Q1 2026 per RANI's latest filing, from -$483000.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $9.4 million in Q4 2025 and bottomed at -$1.7 million in Q1 2026.
- The 5-year median for Other Working Capital Changes is -$407500.0 (2023), against an average of $338312.5.
- Across the five-year window, Other Working Capital Changes soared 62.21% in 2024 and plunged 380.81% in 2025, its largest moves.
- Year by year, Other Working Capital Changes stood at $528000.0 in 2022, then advanced by 1.33% to $535000.0 in 2023, then plunged by 188.97% to -$476000.0 in 2024, then decreased by 1.47% to -$483000.0 in 2025, then rose by 1.24% to -$477000.0 in 2026.
- Per Business Quant, the three latest RANI Other Working Capital Changes figures stand at -$477000.0 (Q1 2026), -$483000.0 (Q4 2025), and -$472000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn |
| 10 | Rani Therapeutics Holdings | 141.49 Mn | 141.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -477,000.00 |
| Mar 31, 2026 | -477,000.00 |
| Mar 31, 2026 | -477,000.00 |
| Dec 31, 2025 | -483,000.00 |
| Dec 31, 2025 | -483,000.00 |
| Dec 31, 2025 | -483,000.00 |
| Sep 30, 2025 | -472,000.00 |
| Sep 30, 2025 | -472,000.00 |
| Sep 30, 2025 | -472,000.00 |
| Jun 30, 2025 | -476,000.00 |
| Jun 30, 2025 | -476,000.00 |
| Jun 30, 2025 | -476,000.00 |
| Mar 31, 2025 | -478,000.00 |
| Mar 31, 2025 | -478,000.00 |
| Mar 31, 2025 | -478,000.00 |
| Dec 31, 2024 | -476,000.00 |
| Dec 31, 2024 | -476,000.00 |
| Dec 31, 2024 | -476,000.00 |
| Sep 30, 2024 | -855,000.00 |
| Sep 30, 2024 | -855,000.00 |